More needs to be done to tackle harmful messaging on the social media platform.TikTok recently announced that it blocked ...

Shares of weight-loss drug developer Metsera gained as much as 25% on Monday after the company's experimental drug helped patients lose weight in a small, early-stage trial, showing potential for a ...

Hims & Hers stock is on the upswing after the company secured a weight-loss drug partnership. Hims & Hers is acquiring its ...

This fast growth has created some high expectations for Hims & Hers stock. It now has a price-to-earnings ratio (P/E) of 79, ...

Rotisserie chickens, hot dogs and milk help drive grocery store traffic.

The team at Omada Health took a victory lap Friday after the company's successful Nasdaq debut, according to company ...

The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other ...

Novo Nordisk NVO has seen strong momentum in recent years, driven by the commercial success of its blockbuster semaglutide ...

He spotted the opportunity to invest in weight-loss drugs in 2023 before they exploded in 2024, and was an early AI mover, which he spied as a game changer in late 2022, early 2023. It's all about ...

Hims & Hers Health sees some volatility with revenue growth, 38% subscriber increase, and promising telehealth market demand.